%A Cheng Lei, Xu Yaping, Mao Weimin %T Molecular targeted therapy of malignant pleural mesothelioma %0 Journal Article %D 2014 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2014.01.017 %P 52-55 %V 41 %N 1 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9280.shtml} %8 2014-01-08 %X Malignant pleural mesothelioma (MPM) is a rare form of cancer with latency period of 20 years, and it is now a period of high flows of MPM. It is often detected in late stages, and the efficacy of surgery, radiotherapy and second/thirdline chemotherapy still remains unknown except the classical firstline chemotherapy regimen contains pemetrexed and cisplatin. With the development of molecular targeted therapy, a new direction for individual therapy of MPM patient has been provided for the past few years.